Skye Bioscience, Correlations
SKYE Stock | USD 2.86 0.15 4.98% |
The current 90-days correlation between Skye Bioscience, Common and Protagonist Therapeutics is 0.03 (i.e., Significant diversification). The correlation of Skye Bioscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Skye Bioscience, Correlation With Market
Significant diversification
The correlation between Skye Bioscience, Common and DJI is 0.09 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Skye Bioscience, Common and DJI in the same portfolio, assuming nothing else is changed.
Skye |
Moving together with Skye Stock
0.73 | PTN | Palatin Technologies | PairCorr |
0.72 | MBIO | Mustang Bio | PairCorr |
0.61 | RANI | Rani Therapeutics | PairCorr |
0.82 | ABOS | Acumen Pharmaceuticals | PairCorr |
0.68 | AQST | Aquestive Therapeutics Buyout Trend | PairCorr |
0.64 | AVDL | Avadel Pharmaceuticals | PairCorr |
Moving against Skye Stock
0.45 | DYAI | Dyadic International | PairCorr |
0.49 | TELO | Telomir Pharmaceuticals, | PairCorr |
0.45 | BNTX | BioNTech SE | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Skye Stock performing well and Skye Bioscience, Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Skye Bioscience,'s multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
META | 1.20 | 0.14 | 0.09 | 0.25 | 1.39 | 3.22 | 8.02 | |||
MSFT | 0.89 | 0.01 | 0.00 | 0.03 | 1.62 | 1.83 | 8.14 | |||
UBER | 1.73 | (0.30) | 0.00 | (0.30) | 0.00 | 2.67 | 20.41 | |||
F | 1.43 | (0.15) | 0.00 | (0.82) | 0.00 | 2.53 | 11.21 | |||
T | 0.97 | 0.06 | 0.04 | 0.29 | 1.16 | 1.93 | 7.95 | |||
A | 1.25 | (0.07) | 0.00 | (0.12) | 0.00 | 2.71 | 9.02 | |||
CRM | 1.54 | 0.42 | 0.25 | 0.31 | 1.29 | 3.59 | 14.80 | |||
JPM | 1.03 | 0.15 | 0.13 | 0.11 | 1.09 | 1.65 | 15.87 | |||
MRK | 0.95 | (0.26) | 0.00 | (1.06) | 0.00 | 1.72 | 5.17 | |||
XOM | 0.91 | (0.12) | 0.00 | (0.35) | 0.00 | 1.83 | 6.06 |
Skye Bioscience, Corporate Management
BA BA | President, Chairman | Profile | |
Kaitlyn CPA | Chief Officer | Profile | |
FACE MD | Chief Officer | Profile | |
Tu MSc | Chief Officer | Profile | |
Christopher Twitty | Chief Officer | Profile |